Last reviewed · How we verify
Selective Therapy: Drug
Selective Therapy: Drug is a Selective therapy Small molecule drug developed by Vanderbilt University Medical Center. It is currently FDA-approved for Various conditions.
Selective therapy targets the drug's molecular mechanism to modulate its activity.
Selective Therapy is a treatment approach that has been studied in various clinical trials for conditions such as depression, epilepsy, and fibromyalgia. The treatment involves a combination of interventions, including cognitive behavioral therapy and physiotherapy protocol, but the specific medication or therapy used is not specified in the available information.
At a glance
| Generic name | Selective Therapy: Drug |
|---|---|
| Sponsor | Vanderbilt University Medical Center |
| Drug class | Selective therapy |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
This approach allows for precise control over the drug's effects, reducing off-target interactions and improving efficacy.
Approved indications
- Various conditions
Common side effects
- Unknown
Key clinical trials
- Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment (PHASE1, PHASE2)
- Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma (PHASE1)
- ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors (PHASE1, PHASE2)
- A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) (PHASE1, PHASE2)
- Autologous SVF Therapy for Type 2 Diabetes (NA)
- Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord Injury (PHASE1, PHASE2)
- Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies (PHASE2)
- IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Selective Therapy: Drug CI brief — competitive landscape report
- Selective Therapy: Drug updates RSS · CI watch RSS
- Vanderbilt University Medical Center portfolio CI
Frequently asked questions about Selective Therapy: Drug
What is Selective Therapy: Drug?
How does Selective Therapy: Drug work?
What is Selective Therapy: Drug used for?
Who makes Selective Therapy: Drug?
What drug class is Selective Therapy: Drug in?
What development phase is Selective Therapy: Drug in?
What are the side effects of Selective Therapy: Drug?
Related
- Drug class: All Selective therapy drugs
- Manufacturer: Vanderbilt University Medical Center — full pipeline
- Indication: Drugs for Various conditions
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing